Frontlight ResearchEarly access
Active, not recruitingPhase 2/3
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Key facts
- Who runs it
- BeOne Medicines
- Where
- Granada Hills, Las Vegas, Minneapolis, and Palo Alto, United StatesSee the 4 sitesAlso in 10 other countries, 49 sites
- Trial code
- NCT05707377
- EU 2022-501147-32-00
- U1111-1285-6790
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 178 people enrolled
- Started
- 17 Apr 2023
- Expected to end
- Oct 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Zanubrutinib
- Tacrolimus
- Record updated
- 11 September 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Biopsy-confirmed PMN within 5 years before the initial screening (ie, the day the informed consent is signed)
- UPCR (based on 24-hour urine collection) > 3.5 at initial screening and at confirmation assessment
- Treatment with a maximally tolerated or allowed dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for ≥ 24 weeks before randomization (12 weeks before initiation of study drug for Part 1) and with adequate blood pressure control (blood pressure < 130/80 mmHg, measured on ≥ 2 occasions [not on the same day] within 4 weeks before the assignment of study treatment)
- Anti-PLA2R antibody > 50 RU/mL at confirmation assessment (Part 1 only)
Who cannot take part
- A known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus (HIV) infection or splenectomy that predisposes the participant to infections
- Patients at risk for tuberculosis at screening
- Known infection with serologic status reflecting active or chronic hepatitis B virus infection, or presence of hepatitis C virus antibody
- Severe hepatic insufficiency (Child-Pugh C)
- Clinically significant cardio-cerebrovascular diseases; Note: Other protocol defined Inclusion/Exclusion criteria may apply
- Type 1 or 2 diabetes mellitus with hemoglobin A1c (HbA1c) ≥ 7% at screening
- Severe renal disease as determined by rapid decline in eGFR (defined as > 15 mL/min/1.73m\^2 within 24 weeks prior to randomization, not otherwise explained)
- Participants with a secondary cause of membranous nephropathy
Where in United States
Also in 10 other countries, 49 sites
- Amicis Research CenterGranada Hills, United States
- Kidney Specialist of Southern Nevada (Ksosn)Las Vegas, United States
- Intermed ConsultantsMinneapolis, United States
- Stanford UniversityPalo Alto, United States
About the trial
What the trial wants to find out
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
The 4 groups in the trial
- Part 1: Zanubrutinib High DoseTreatment being tested
Participants will receive zanubrutinib twice daily.
Treatment: Zanubrutinib
- Part 2: Zanubrutinib High DoseTreatment being tested
Participants will receive zanubrutinib twice daily.
Treatment: Zanubrutinib
- Part 2: Zanubrutinib Low DoseTreatment being tested
Participants will receive zanubrutinib once daily.
Treatment: Zanubrutinib
- Part 2: TacrolimusExisting treatment, for comparison
Participants will receive tacrolimus capsules twice daily for 64 weeks.
Treatment: Tacrolimus
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
- Publications
- Targeting B Cells and Plasma Cells in Glomerular Disease.Journal of the American Society of Nephrology : JASN, 2025
- Record updated
- 11 September 2026